The neurotrophin receptor p75NTR is induced on mature myofibres in inflammatory myopathies and promotes myotube survival to inflammatory stress

Neuropathology and Applied Neurobiology

Volumn 38, Issue 4, 2012, Pages 367-378

  Colombo, E ^a,b   Romaggi, S ^a   Blasevich, F ^a   Mora, M ^a   Falcone, C ^a   Lochmuller H ^c   Morandi, L ^a   Farina, C ^a,b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Human skeletal muscle; Inflammation; Myositis; P75NTR

Indexed keywords

DYSTROPHIN; INTERLEUKIN 1; NEUROTROPHIN RECEPTOR P75;

ADULT; ARTICLE; BECKER MUSCULAR DYSTROPHY; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; DERMATOMYOSITIS; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; MUSCLE BIOPSY; MUSCLE CELL; MYOTUBE; POLYMERASE CHAIN REACTION; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SATELLITE CELL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRESS; UPREGULATION;

ADOLESCENT; ADULT; AGED; CELL SURVIVAL; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; MYOFIBRILS; MYOSITIS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; RECEPTORS, NERVE GROWTH FACTOR; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84860899688     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01212.x     Document Type: Article

References (56)

1. Dechant G, Barde YA. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci 2002; 5: 1131-6.
2. Wang XH, Poo MM. Potentiation of developing synapses by postsynaptic release of neurotrophin-4. Neuron 1997; 19: 825-35.
3. Xie K, Wang T, Olafsson P, Mizuno K, Lu B. Activity-dependent expression of NT-3 in muscle cells in culture: implications in the development of neuromuscular junctions. J Neurosci 1997; 17: 2947-58.
4. Gonzalez M, Ruggiero FP, Chang Q, Shi YJ, Rich MM, Kraner S, Balice-Gordon RJ. Disruption of trkb-mediated signaling induces disassembly of postsynaptic receptor clusters at neuromuscular junctions. Neuron 1999; 24: 567-83.
5. Henderson CE, Yamamoto Y, Livet J, Arce V, Garces A, deLapeyriere O. Role of neurotrophic factors in motoneuron development. J Physiol Paris 1998; 92: 279-81.
6. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000; 14: 2919-37.
7. Deponti D, Buono R, Catanzaro G, De Palma C, Longhi R, Meneveri R, Bresolin N, Bassi MT, Cossu G, Clementi E, Brunelli S. The low-affinity receptor for neurotrophins p75NTR plays a key role for satellite cell function in muscle repair acting via RhoA. Mol Biol Cell 2009; 20: 3620-7.
8. Colombo E, Romaggi S, Medico E, Menon R, Mora M, Falcone C, Lochmuller H, Confalonieri P, Mantegazza R, Morandi L, Farina C. The human neurotrophin receptor p75NTR defines differentiation-oriented skeletal muscle precursor cells: implications for muscle regeneration. J Neuropathol Exp Neurol 2011; 70: 133-42.
9. Mousavi K, Jasmin BJ. BDNF is expressed in skeletal muscle satellite cells and inhibits myogenic differentiation. J Neurosci 2006; 26: 5739-49.
10. Baron P, Scarpini E, Meola G, Santilli I, Conti G, Pleasure D, Scarlato G. Expression of the low-affinity NGF receptor during human muscle development, regeneration, and in tissue culture. Muscle Nerve 1994; 17: 276-84.
11. Heuss D. Light microscopy study of low-affinity nerve growth factor receptor and phosphoprotein B-50/neuromodulin in inflammatory myopathies. Acta Neuropathol (Berl) 1996; 91: 409-15.
12. Toti P, Villanova M, Vatti R, Schuerfeld K, Stumpo M, Barbagli L, Malandrini A, Costantini M. Nerve growth factor expression in human dystrophic muscles. Muscle Nerve 2003; 27: 370-3.
13. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-98.
14. Engel A. Franzini-Armstrong C. Myology. New York, NY: McGraw-Hill, 1994.
15. Berzi A, Ayata CK, Cavalcante P, Falcone C, Candiago E, Motta T, Bernasconi P, Hohlfeld R, Mantegazza R, Meinl E, Farina C. BDNF and its receptors in human myasthenic thymus: implications for cell fate in thymic pathology. J Neuroimmunol 2008; 197: 128-39.
16. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82.
17. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620-31.
18. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998; 24: 73-9.
19. Tucci M, Quatraro C, Dammacco F, Silvestris F. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann N Y Acad Sci 2007; 1107: 184-92.
20. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865-74.
21. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999; 9: 239-46.
22. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131: 1228-40.
23. Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007; 56: 674-87.
24. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 2004; 5: 872-6.
25. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349-63.
26. Pinzani M, Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis 2008; 12: 901-13.
27. Dalakas MC. The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001; 1: 300-6.
28. Balabaud C, Bioulac-Sage P, Desmouliere A. The role of hepatic stellate cells in liver regeneration. J Hepatol 2004; 40: 1023-6.
29. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 2004; 164: 1007-19.
30. Passino MA, Adams RA, Sikorski SL, Akassoglou K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 2007; 315: 1853-6.
31. Sachs BD, Baillie GS, McCall JR, Passino MA, Schachtrup C, Wallace DA, Dunlop AJ, MacKenzie KF, Klussmann E, Lynch MJ, Sikorski SL, Nuriel T, Tsigelny I, Zhang J, Houslay MD, Chao MV, Akassoglou K. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J Cell Biol 2007; 177: 1119-32.
32. Kendall TJ, Hennedige S, Aucott RL, Hartland SN, Vernon MA, Benyon RC, Iredale JP. p75 neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology 2009; 49: 901-10.
33. Flugel A, Matsumuro K, Neumann H, Klinkert WE, Birnbacher R, Lassmann H, Otten U, Wekerle H. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 2001; 31: 11-22.
34. Caroleo MC, Costa N, Bracci-Laudiero L, Aloe L. Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors. J Neuroimmunol 2001; 113: 193-201.
35. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci U S A 1998; 95: 5779-84.
36. Apte RN, Voronov E. Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002; 12: 277-90.
37. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503-8.
38. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-99.
39. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-6.
40. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 2001; 15: 1169-80.
41. Broussard SR, McCusker RH, Novakofski JE, Strle K, Shen WH, Johnson RW, Dantzer R, Kelley KW. IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts. J Immunol 2004; 172: 7713-20.
42. Llovera M, Carbo N, Lopez-Soriano J, Garcia-Martinez C, Busquets S, Alvarez B, Agell N, Costelli P, Lopez-Soriano FJ, Celada A, Argiles JM. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 1998; 133: 83-7.
43. Li W, Moylan JS, Chambers MA, Smith J, Reid MB. Interleukin-1 stimulates catabolism in C2C12 myotubes. Am J Physiol Cell Physiol 2009; 297: C706-14.
44. Glass DJ. A signaling role for dystrophin: inhibiting skeletal muscle atrophy pathways. Cancer Cell 2005; 8: 351-2.
45. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8: 421-32.
46. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3: 1009-13.
47. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287: E591-601.
48. Dehoux M, Gobier C, Lause P, Bertrand L, Ketelslegers JM, Thissen JP. IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA. Am J Physiol Endocrinol Metab 2007; 292: E145-E150.
49. Tidball JG, Albrecht DE, Lokensgard BE, Spencer MJ. Apoptosis precedes necrosis of dystrophin-deficient muscle. J Cell Sci 1995; 108 (Pt 6): 2197-204.
50. Tews DS, Goebel HH. Apoptosis-related proteins in skeletal muscle fibers of spinal muscular atrophy. J Neuropathol Exp Neurol 1997; 56: 150-6.
51. Sandri M, Minetti C, Pedemonte M, Carraro U. Apoptotic myonuclei in human Duchenne muscular dystrophy. Lab Invest 1998; 78: 1005-16.
52. Sandri M, El Meslemani AH, Sandri C, Schjerling P, Vissing K, Andersen JL, Rossini K, Carraro U, Angelini C. Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment? J Neuropathol Exp Neurol 2001; 60: 302-12.
53. Schneider C, Gold R, Dalakas MC, Schmied M, Lassmann H, Toyka KV, Hartung HP. MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 1996; 55: 1205-9.
54. Behrens L, Bender A, Johnson MA, Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997; 120 (Pt 6): 929-38.
55. Hutchinson DO. Inclusion body myositis: abnormal protein accumulation does not trigger apoptosis. Neurology 1998; 51: 1742-5.
56. De Bleecker JL, Meire VI, Van Walleghem IE, Groessens IM, Schroder JM. Immunolocalization of FAS and FAS ligand in inflammatory myopathies. Acta Neuropathol (Berl) 2001; 101: 572-8.